Compensation award — excluded from discretionary-purchase analysis.
Loading…
Amy E. Herr is Director at Bio-Techne. OQRO lists 15 transactions filed with the SEC under this name, the latest on Aug 19, 2026, each linked to the official Form 4.
Director
Disclosures on record
15
Companies involved
1
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Stock since the trade +50.1% · S&P 500 +5.0% · to Oct 5
A board member of Bio-Techne sold $320K of Bio-Techne shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Stock since the trade +24.1% · S&P 500 +13.5% · to Oct 5
A board member of Bio-Techne sold $117K of Bio-Techne shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.